Phase 2/3CompletedAge-related condition
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy (EUROCONDOR)
Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy:Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent/Arrest Diabetic Retinopathy
- Sponsor
- BCN Peptides (Industry)
- Enrollment
- 450 enrolled
- Conditions
- Diabetic Retinopathy
- Interventions
- COLIRIOBCN070660; Placebo; Brimonidine
- Ages
- adults, older adults
- Registry
- NCT01726075, EUCTR2012-001200-38
Full record on ClinicalTrials.gov
From the registry
To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes
Primary outcomes
- Changes in the Implicit Time assessed by mfERG (IT-mfERG) at month 6, 12, 18 and 24
History
Last registry update
Primary completion
Started
Registered